JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD

JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD (China) holds 23 active US FDA Type II Drug Master Files and has DMF or CEP filings on record for 2 active ingredients. No FDA recall, Warning Letter or Form 483 record is linked to it, which is not proof that none exists.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/jiangsu-east-mab-biomedical-technology-co-ltd

Overview

JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD is an active pharmaceutical ingredient (API) supplier with 23 active FDA Type II Drug Master Files, covering RECOMBINANT ANTI-HUMAN CD16 MAB; RECOMBINANT ANTI-HUMAN CD28 MAB; RECOMBINANT ANTI-HUMAN CD3 MAB; RECOMBINANT HUMAN ACTIVIN A; RECOMBINANT HUMAN BFGF; RECOMBINANT HUMAN BMP 2.

Core services & business areas

API Manufacturing

Active ingredients with DMF or CEP filings

Substances for which JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD holds 23 active (23 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • RECOMBINANT HUMAN TRANSFERRINActive2025-08-13
  • RECOMBINANT HUMAN M-CSF (E. COLI-EXPRESSED)Active2025-07-17
  • RECOMBINANT HUMAN BMP 2Active2025-03-27
  • RECOMBINANT HUMAN IL-18 (E.COLI-EXPRESSED)Active2025-03-27
  • RECOMBINANT HUMAN INTERLEUKIN-7Active2025-03-27
  • RECOMBINANT HUMAN IFNYActive2025-03-05
  • RECOMBINANT ANTI-HUMAN CD3 MABActive2025-03-04
  • RECOMBINANT HUMAN IL-1A (E.COLI-EXPRESSED)Active2025-02-24
  • RECOMBINANT HUMAN G-CSFActive2024-09-24
  • RECOMBINANT HUMAN GM-CSFActive2024-09-21
  • RECOMBINANT HUMAN INTERLEUKIN-12Active2024-09-20
  • RECOMBINANT HUMAN BFGFActive2024-09-11
  • RECOMBINANT HUMAN PDGF-BBActive2024-09-08
  • RECOMBINANT HUMAN TPOActive2024-09-07
  • RECOMBINANT ANTI-HUMAN CD28 MABActive2024-09-04
  • RECOMBINANT HUMAN TGF-ß1Active2024-09-02
  • RECOMBINANT ANTI-HUMAN CD16 MABActive2024-08-31
  • RECOMBINANT HUMAN ACTIVIN AActive2024-08-28
  • RECOMBINANT HUMAN INTERLEUKIN-15Active2024-08-25
  • RECOMBINANT HUMAN LR3-IGF1Active2024-08-25
  • RECOMBINANT HUMAN VEGF165Active2024-08-14
  • RECOMBINANT HUMAN INTERLEUKIN-21Active2024-08-14
  • RECOMBINANT HUMAN IL-2 PROTEINActive2024-06-30

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.

For suppliers

Is this JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.